CSIMarket


Pardes Biosciences Inc   (PRDS)
Other Ticker:  
 


 

Pardes Biosciences Inc

PRDS's Financial Statements and Analysis



Pardes Biosciences Inc narrowed second quarter of 2023 net loss per share of $-0.18 compare to net loss per share of $-0.48 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.30 realized in previous quarter.


second quarter of 2023
Earnings Per Share Revenues
$ -0.18 $  0 Mill
$+0.30     Unch.    



Pardes Biosciences Inc 's Revenue fell by 0 % in second quarter of 2023 (Jun 30 2023) year on year, to $0 million and declined by sequentially.


Pardes Biosciences Inc is

More on PRDS's Income Statement



Pardes Biosciences Inc 's in thesecond quarter of 2023 recorded net loss of $-10.775 million, an improvement compare to net loss of $-27.637 million in II. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-17.805 million realized in previous quarter.

More on PRDS's Growth

Pardes Biosciences Inc Inventories
PRDS's Cash flow In the second quarter of 2023 company's net cash flow was $53 million


Pardes Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Pardes Biosciences Inc payed $ -0.11 cash per share, on a free-cash flow basis .

Book value fell by -6.37 % sequentially to $2.58 per share, -15.54% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.58 per share from $ 2.76.

Company issued 0.44 million shares or 0.74 % in Jun 30 2023.
Interest Coverage Ratio was 6.33.

More on PRDS's Dividends

 Market Capitalization (Millions) 130
 Shares Outstanding (Millions) 60
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -76
 Cash Flow (TTM) (Millions $) 81
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Pardes Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Pardes Biosciences Inc had negative $ -0.11 cash flow per share, on a free-cash flow basis .

Book value fell by -6.37 % sequentially to $2.58 per share, -15.54% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.58 per share from $ 2.76.

Company issued 0.44 million shares or 0.74 % in Jun 30 2023.
Interest Coverage Ratio was 6.33.

More on PRDS's Balance Sheets

 Market Capitalization (Millions) 130
 Shares Outstanding (Millions) 60
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -76
 Cash Flow (TTM) (Millions $) 81
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Pardes Biosciences Inc Earnings

PRDS Unveils Q2 2023 Financial Results, Revealing an Unexpected Operating Loss of $12.615 Million - A Twist in Pharmaceutical Industry Saga

Investors Eye Positive Surprises in Pardes Biosciences' Financial Performance
August 7, 2023
Pardes Biosciences Inc, a major pharmaceutical preparations company, has recently released its financial results for the earnings cycle of fiscal April to June 2023. While stockholders did not anticipate any modifications at the top-line, they have been closely monitoring the company's operating loss.
To the delight of investors, Pardes Biosciences reported an operating loss of $-12.615 million for the period, indicating a significant improvement when compared to the $-27.935 million loss recorded in the same quarter the previous year. This indicates that the company has been able to work more efficiently...

Pardes Biosciences Inc: A Major Pharmaceutical Preparations Company Struggles to Overcome Financial Challenges

Pardes Biosciences Inc, a major pharmaceutical preparations company, recently reported a cumulative net loss of $-93 million for the 12 months ending in the third quarter of 2023, resulting in a negative return on investment (ROI) of -48.34%. This puts Pardes Biosciences Inc behind 201 other companies in the healthcare sector with a higher return on investmentHowever, there seems to be some improvement in the company's ROI ranking, which has progressed to 1723 in the Mar 31 2023 quarter, up from the total ROI ranking in the fourth quarter of 2022 at 4154.
Directing our attention towards the financial third quarter of 2023, Par...


Date modified: 2023-08-05T18:43:50+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com